A method for forming a droplet interface bilayer (DIB) comprises the steps of: (1) providing an assembly that includes a housing contained within an enclosure, wherein the housing includes at least one aperture that comprises a cis portion and a trans portion, at least one cis electrode receptacle and at least one trans electrode receptacle, wherein the cis electrode receptacle is operatively connected to the cis portion, and the trans electrode receptacle is operatively connected to the trans portion; (2) inserting an electrode into each of the cis and trans electrode receptacles; (3) introducing an oil/lipid phase to the enclosure such that the oil/lipid phase flows into the housing through the aperture; (4) delivering at least two aqueous droplets to the oil/lipid phase in such a manner that at least one aqueous droplet is disposed within the cis portion of the aperture and at least one aqueous droplet is disposed within the trans portion of the aperture; and (5) lowering a level of the oil/lipid phase in the cis and trans portions of the aperture to cause the aqueous droplets in the cis and trans portions to expand and move closer to one another until the aqueous droplets contact one another thereby forming the lipid bilayer at the location at which the aqueous droplets contact one another.

The present disclosure provides methods and systems for detecting melanoma in a host. The methods include non-invasive methods of detecting melanoma and methods and systems for providing a molecular signature and/or melanoma biomarker signature for a host.

The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing pancreas cancer in a subject and, preferably for differentiating between pancreatic cancer and pancreatitis and a method for identifying whether a subject is in need for a therapy of pancreatic cancer. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

Disclosed are methods of, and assay and kits for, detecting and diagnosing methods of detecting, diagnosing, vulnerable carotid artery disease capable of becoming acutely symptomatic using the levels of Resolvin D1 (RvD1), docosahexaenoic acid (DHA), and arachidonic acid (AA). Also disclosed are methods of treating carotid artery disease and methods of identifying agents for use in the treatment of carotid artery disease.

The present invention relates to a method for determining the lipophilicity of a test compound comprising the steps of: a) providing a multiwell plate, wherein the wells comprise at the bottom a lipophilic membrane and the bottom of the multiwell plate comprises a liquid tight barrier to produce a liquid tight bottom of the multiwell plate, b) adding a non-polar solvent to the lipophilic membranes in the wells of step a), c) adding an aqueous solution comprising the test compound to the wells of step b, and d) determining the quantity of the test compound in the aqueous solution after a distribution equilibrium has been reached.

Disclosed are a method and a reagent for quantifying HDL3 in a test sample without requiring laborious operations. The method for quantifying cholesterol in high-density lipoprotein 3 comprises reacting a test sample with one or more surfactants which react specifically with high-density lipoprotein 3, and quantifying cholesterol. When one surfactant is used, the surfactant is one selected from the group consisting of polyoxyethylene polycyclic phenyl ethers having an HLB of 12.5 to 15. When two or more surfactants are used, at least one of the surfactants is at least one selected from the group consisting of polyoxyethylene polycyclic phenyl ethers, and the two or more surfactants are combined so as to provide the total HLB of 12.5 to 15 of the combined surfactants.

The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.

The method of this invention relates a method of diagnosing a patient as having post-traumatic stress disorder (PTSD) and/or treating the patient therapeutically for PTSD. In one embodiment, the treatment involves administering a therapeutically effective amount of bufodienolide antagonist to the patient.

A method is described for diagnosing eosinophilic esophagitis by studying the levels of expression of novel markers, including ALOX15 or metabolites thereof, TNFAIP6, FLG, SLURP1, or CRISP3. Also described are methods for treating eosinophilic esophagitis.

A method for forming a droplet interface bilayer (DIB) comprises the steps of: (1) providing an assembly that includes a housing contained within an enclosure, wherein the housing includes at least one aperture that comprises a cis portion and a trans portion, at least one cis electrode receptacle and at least one trans electrode receptacle, wherein the cis electrode receptacle is operatively connected to the cis portion, and the trans electrode receptacle is operatively connected to the trans portion; (2) inserting an electrode into each of the cis and trans electrode receptacles; (3) introducing an oil/lipid phase to the enclosure such that the oil/lipid phase flows into the housing through the aperture; (4) delivering at least two aqueous droplets to the oil/lipid phase in such a manner that at least one aqueous droplet is disposed within the cis portion of the aperture and at least one aqueous droplet is disposed within the trans portion of the aperture; and (5) lowering a level of the oil/lipid phase in the cis and trans portions of the aperture to cause the aqueous droplets in the cis and trans portions to expand and move closer to one another until the aqueous droplets contact one another thereby forming the lipid bilayer at the location at which the aqueous droplets contact one another.